Trans Medics Group, Inc. TMDX
We take great care to ensure that the data presented and summarized in this overview for TransMedics Group, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TMDX
View all-
Black Rock Inc. New York, NY2.52MShares$344 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.89MShares$258 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C31.3MShares$177 Million0.11% of portfolio
-
Driehaus Capital Management LLC Chicago, IL1.28MShares$175 Million1.04% of portfolio
-
Invesco Ltd. Atlanta, GA1.28MShares$175 Million0.02% of portfolio
-
Eventide Asset Management, LLC Boston, MA1.17MShares$160 Million1.4% of portfolio
-
Arrow Mark Colorado Holdings LLC Denver, CO1.08MShares$147 Million0.99% of portfolio
-
Credit Suisse Ag Zurich, V8848KShares$116 Million0.06% of portfolio
-
State Street Corp Boston, MA775KShares$106 Million0.0% of portfolio
-
Sandhill Capital Partners LLC Buffalo, NY734KShares$100 Million4.51% of portfolio
Latest Institutional Activity in TMDX
Top Purchases
Top Sells
About TMDX
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Insider Transactions at TMDX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 29
2024
|
David Weill |
SELL
Open market or private sale
|
Direct |
1,193
-10.0%
|
$168,213
$141.65 P/Share
|
|
May 29
2024
|
Stephen Gordon Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
20,000
-20.42%
|
$2,820,000
$141.38 P/Share
|
|
May 29
2024
|
Stephen Gordon Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,000
+10.02%
|
$774,000
$43.42 P/Share
|
|
May 23
2024
|
Edward M Basile |
BUY
Grant, award, or other acquisition
|
Direct |
732
+27.55%
|
-
|
|
May 23
2024
|
David Weill |
BUY
Grant, award, or other acquisition
|
Direct |
732
+5.78%
|
-
|
|
May 23
2024
|
Stephanie Lovell |
BUY
Grant, award, or other acquisition
|
Direct |
732
+27.55%
|
-
|
|
May 23
2024
|
Edwin M Kania Jr |
BUY
Grant, award, or other acquisition
|
Direct |
732
+0.28%
|
-
|
|
May 23
2024
|
Merilee Raines |
BUY
Grant, award, or other acquisition
|
Direct |
732
+27.55%
|
-
|
|
May 23
2024
|
James R Tobin |
BUY
Grant, award, or other acquisition
|
Direct |
732
+27.55%
|
-
|
|
May 23
2024
|
Thomas James Gunderson |
BUY
Grant, award, or other acquisition
|
Direct |
732
+27.55%
|
-
|
|
May 15
2024
|
Waleed H Hassanein President & CEO |
SELL
Open market or private sale
|
Direct |
8,625
-3.17%
|
$1,155,750
$134.98 P/Share
|
|
May 15
2024
|
Waleed H Hassanein President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
8,625
+10.93%
|
$112,125
$13.28 P/Share
|
|
May 10
2024
|
David Weill |
SELL
Open market or private sale
|
Direct |
2,500
-18.26%
|
$322,500
$129.82 P/Share
|
|
May 07
2024
|
Edward M Basile |
SELL
Open market or private sale
|
Direct |
7,157
-31.89%
|
$930,410
$130.44 P/Share
|
|
May 06
2024
|
Nicholas Corcoran |
SELL
Open market or private sale
|
Direct |
3,222
-13.24%
|
$415,638
$129.91 P/Share
|
|
May 06
2024
|
Waleed H Hassanein President & CEO |
SELL
Open market or private sale
|
Direct |
30,000
-32.74%
|
$3,900,000
$130.07 P/Share
|
|
May 06
2024
|
Waleed H Hassanein President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+24.66%
|
$390,000
$13.28 P/Share
|
|
May 06
2024
|
Tamer I Khayal Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
5,839
-37.36%
|
$759,070
$130.07 P/Share
|
|
May 06
2024
|
Tamer I Khayal Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,839
+27.2%
|
$385,374
$66.1 P/Share
|
|
May 06
2024
|
Stephen Gordon Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
15,000
-39.17%
|
$1,920,000
$128.0 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 87.1K shares |
|---|---|
| Exercise of conversion of derivative security | 341K shares |
| Open market or private purchase | 2.5K shares |
| Bona fide gift | 7.5K shares |
|---|---|
| Open market or private sale | 504K shares |